
Shattuck Labs Q2 loss reaches $15.2 million
- Shattuck Labs reported a Q2 2026 net loss of $15.2 million with no revenue, while cash and investments reached $208.3 million.
- No verified post-results STTK trade was available, with the latest market price at $7.14.
- Shattuck expects its RECEPTIVE-CD1 Phase 2b Crohn’s disease trial to begin in Q3 2026, with 12-week data expected in H1 2028.
Shattuck Labs (NASDAQ:STTK) reported a $15.2 million Q2 2026 net loss with no revenue while advancing lead candidate SL-325.
The loss increased slightly from $14.8 million in Q1, while cash and investments rose from $90.4 million to $208.3 million.
Phase 1 data showed 3.7% antidrug antibody incidence, blockade beyond three months at doses of at least 1 mg/kg and no DR3 agonism.
Shattuck expects the roughly 232-patient RECEPTIVE-CD1 Phase 2b trial to start in Q3 2026, with 12-week endoscopic-response data in H1 2028.
Shattuck is also advancing DR3 x IL-23R bispecific SL-846 through GLP toxicology and expects to begin Phase 1 development in 2027.
The company strengthened its balance sheet through an upsized June equity offering and warrant exercises, with management expecting funding to extend into 2029.
Frequently asked questions
More from United States
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab
DataMeds AI issues 630,000 shares in cancer partnership
CoinShares net income improves 27% to $39.6 million
newcleo revenue skyrockets 26% to €10 million in Q3

